Abstract
Abemaciclib is approved for HR+/HER2- metastatic breast cancer in combination with endocrine therapy (ET). We evaluated safety and efficacy of abemaciclib in association with ET in a single-institution cohort.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of oncology : official journal of the European Society for Medical Oncology
Paper Title
Journal
Date
